Medarex Announces Presentations At The 33rd Congress Of The European Society For Medical Oncology

Main Category: Melanoma / Skin Cancer
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 05 Sep 2008 - 3:00 PDT

email to a friend   printer friendly   opinions  

Medarex, Inc. (Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of the European Society for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm. Many of the following abstracts will include updated one-year survival data from three Phase 2 studies (008, 022 and 007) in previously treated patients with advanced metastatic melanoma:

Ipilimumab Presentations in Advanced Melanoma

-- "Efficacy and safety of patients with advanced melanoma treated with ipilimumab with or without the addition of prophylactic budesonide" (Abstract #783P) I. Ron - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy" (Abstract #787P) K. Chin - Poster discussion from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Ipilimumab-mediated patterns of response in patients with pretreated, advanced melanoma" (Abstract #784P) K. Harmankaya - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases" (Abstract #786P) J. S. Weber - Poster presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma" (Abstract #785P) A. Hoos - Poster presentation and discussion from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.

-- "Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma - results from a Phase 2, randomized, dose-ranging study" (Abstract #769O) C. Lebbe - Oral presentation from 3:30 p.m. to 5:30 p.m. local time on Monday, September 15, 2008.

-- "Efficacy and safety of treatment-naive and previously treated patients with advanced melanoma receiving ipilimumab" (Abstract #778PD) R. Ridolfi - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15, 2008.

-- "Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study" (Abstract #776PD) M. Maio - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15, 2008.

-- "Prolonged stable disease in ipilimumab-treated patients with advanced melanoma who have progressed on prior anticancer therapies" (Abstract #768O) V. Chiarion Sileni - Oral presentation from 3:30 p.m. to 5:30 p.m. local time on Monday, September 15, 2008.

More information about the ESMO Congress may be found at http://www.esmo.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

Medarex, Inc.
http://www.medarex.com

• Additional
• References
• Citations